Literature DB >> 24305876

FGFR1-WNT-TGF-β signaling in prostate cancer mouse models recapitulates human reactive stroma.

Julienne L Carstens1, Payam Shahi, Susan Van Tsang, Billie Smith, Chad J Creighton, Yiqun Zhang, Amber Seamans, Mamatha Seethammagari, Indira Vedula, Jonathan M Levitt, Michael M Ittmann, David R Rowley, David M Spencer.   

Abstract

The reactive stroma surrounding tumor lesions performs critical roles ranging from supporting tumor cell proliferation to inducing tumorigenesis and metastasis. Therefore, it is critical to understand the cellular components and signaling control mechanisms that underlie the etiology of reactive stroma. Previous studies have individually implicated fibroblast growth factor receptor 1 (FGFR1) and canonical WNT/β-catenin signaling in prostate cancer progression and the initiation and maintenance of a reactive stroma; however, both pathways are frequently found to be coactivated in cancer tissue. Using autochthonous transgenic mouse models for inducible FGFR1 (JOCK1) and prostate-specific and ubiquitously expressed inducible β-catenin (Pro-Cat and Ubi-Cat, respectively) and bigenic crosses between these lines (Pro-Cat × JOCK1 and Ubi-Cat × JOCK1), we describe WNT-induced synergistic acceleration of FGFR1-driven adenocarcinoma, associated with a pronounced fibroblastic reactive stroma activation surrounding prostatic intraepithelial neoplasia (mPIN) lesions found both in in situ and reconstitution assays. Both mouse and human reactive stroma exhibited increased transforming growth factor-β (TGF-β) signaling adjacent to pathologic lesions likely contributing to invasion. Furthermore, elevated stromal TGF-β signaling was associated with higher Gleason scores in archived human biopsies, mirroring murine patterns. Our findings establish the importance of the FGFR1-WNT-TGF-β signaling axes as driving forces behind reactive stroma in aggressive prostate adenocarcinomas, deepening their relevance as therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24305876      PMCID: PMC3905049          DOI: 10.1158/0008-5472.CAN-13-1093

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.

Authors:  Xinhai Wan; Jie Liu; Jing-Fang Lu; Vassiliki Tzelepi; Jun Yang; Michael W Starbuck; Lixia Diao; Jing Wang; Eleni Efstathiou; Elba S Vazquez; Patricia Troncoso; Sankar N Maity; Nora M Navone
Journal:  Clin Cancer Res       Date:  2012-02-01       Impact factor: 12.531

2.  Detection and analysis of beta-catenin mutations in prostate cancer.

Authors:  D R Chesire; C M Ewing; J Sauvageot; G S Bova; W B Isaacs
Journal:  Prostate       Date:  2000-12-01       Impact factor: 4.104

3.  A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo.

Authors:  J Zhang; T Z Thomas; S Kasper; R J Matusik
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

4.  Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions.

Authors:  Xiaohong Li; Julie A Sterling; Kang-Hsien Fan; Robert L Vessella; Yu Shyr; Simon W Hayward; Lynn M Matrisian; Neil A Bhowmick
Journal:  Mol Cancer Res       Date:  2012-01-30       Impact factor: 5.852

5.  FGF signaling regulates mesoderm cell fate specification and morphogenetic movement at the primitive streak.

Authors:  B Ciruna; J Rossant
Journal:  Dev Cell       Date:  2001-07       Impact factor: 12.270

6.  Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells.

Authors:  David J Mulholland; Naoko Kobayashi; Marcus Ruscetti; Allen Zhi; Linh M Tran; Jiaoti Huang; Martin Gleave; Hong Wu
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

7.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Authors:  Michael Ittmann; Jiaoti Huang; Enrico Radaelli; Philip Martin; Sabina Signoretti; Ruth Sullivan; Brian W Simons; Jerrold M Ward; Brian D Robinson; Gerald C Chu; Massimo Loda; George Thomas; Alexander Borowsky; Robert D Cardiff
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

8.  Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.

Authors:  Yu Sun; Judith Campisi; Celestia Higano; Tomasz M Beer; Peggy Porter; Ilsa Coleman; Lawrence True; Peter S Nelson
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440

9.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

10.  Activation of Wnt signaling by chemically induced dimerization of LRP5 disrupts cellular homeostasis.

Authors:  Payam Shahi; Dongsu Park; Adam C Pond; Mamatha Seethammagari; Shin-Heng Chiou; Kyucheol Cho; Julienne L Carstens; William K Decker; Pierre D McCrea; Michael M Ittmann; Jeffrey M Rosen; David M Spencer
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

View more
  19 in total

Review 1.  Cellular determinants and microenvironmental regulation of prostate cancer metastasis.

Authors:  Kiera Rycaj; Hangwen Li; Jianjun Zhou; Xin Chen; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2017-04-11       Impact factor: 15.707

Review 2.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

3.  Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer: author reply.

Authors:  A Berlin; A Dal Pra; R G Bristow
Journal:  Br J Radiol       Date:  2015-01       Impact factor: 3.039

4.  PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.

Authors:  Matthew T Jefferies; Adam C Cox; Boris Y Shorning; Valerie Meniel; David Griffiths; Howard G Kynaston; Matthew J Smalley; Alan R Clarke
Journal:  J Pathol       Date:  2017-11-14       Impact factor: 7.996

5.  Discovery of Stromal Regulatory Networks that Suppress Ras-Sensitized Epithelial Cell Proliferation.

Authors:  Huayang Liu; James A Dowdle; Safiya Khurshid; Nicholas J Sullivan; Nicholas Bertos; Komal Rambani; Markus Mair; Piotr Daniel; Esther Wheeler; Xing Tang; Kyle Toth; Michael Lause; Markus E Harrigan; Karl Eiring; Connor Sullivan; Matthew J Sullivan; Serena W Chang; Siddhant Srivastava; Joseph S Conway; Raleigh Kladney; Joseph McElroy; Sooin Bae; Yuanzhi Lu; Ali Tofigh; Sadiq M I Saleh; Soledad A Fernandez; Jeffrey D Parvin; Vincenzo Coppola; Erin R Macrae; Sarmila Majumder; Charles L Shapiro; Lisa D Yee; Bhuvaneswari Ramaswamy; Michael Hallett; Michael C Ostrowski; Morag Park; Helen M Chamberlin; Gustavo Leone
Journal:  Dev Cell       Date:  2017-05-22       Impact factor: 12.270

Review 6.  Cellular plasticity and the neuroendocrine phenotype in prostate cancer.

Authors:  Alastair H Davies; Himisha Beltran; Amina Zoubeidi
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

7.  Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment.

Authors:  Yu-Chen Lee; Martina Srajer Gajdosik; Djuro Josic; James G Clifton; Christopher Logothetis; Li-Yuan Yu-Lee; Gary E Gallick; Sankar N Maity; Sue-Hwa Lin
Journal:  Mol Cell Proteomics       Date:  2014-12-19       Impact factor: 5.911

Review 8.  From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer.

Authors:  Chuan Yu; Kevin Hu; Daniel Nguyen; Zhu A Wang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

9.  Expression and colocalization of β-catenin and lymphoid enhancing factor-1 in prostate cancer progression.

Authors:  Tyler M Bauman; Chad M Vezina; Emily A Ricke; Richard B Halberg; Wei Huang; Richard E Peterson; William A Ricke
Journal:  Hum Pathol       Date:  2016-01-19       Impact factor: 3.466

Review 10.  The many ways to make a luminal cell and a prostate cancer cell.

Authors:  Douglas W Strand; Andrew S Goldstein
Journal:  Endocr Relat Cancer       Date:  2015-08-25       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.